5919-84-6

Basic information

• Product Name: 3-hydroxy-2,2-dimethylpropyl isobutyrate
• Synonyms: 3-hydroxy-2,2-dimethylpropyl isobutyrate;2-Methylpropanoic acid 3-hydroxy-2,2-dimethylpropyl ester;Ai3-28488;Einecs 227-643-1;Neopentyl glycol monoisobutyrate;Propanoic acid, 2-methyl-, 3-hydroxy-2,2-dimethylpropyl ester
• CAS NO: 5919-84-6
• Molecular Formula: C₉H₁₈O₃
• Molecular Weight: 174.23742
• EINECS: 227-643-1
• Mol File: 5919-84-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 198.7°C at 760 mmHg
• Flash Point: 65.4°C
• Appearance: /
• Density: 0.976g/cm³
• Vapor Pressure: 0.0892mmHg at 25°C
• Refractive Index: 1.439
• CAS DataBase Reference: 3-hydroxy-2,2-dimethylpropyl isobutyrate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-hydroxy-2,2-dimethylpropyl isobutyrate(5919-84-6)
• EPA Substance Registry System: 3-hydroxy-2,2-dimethylpropyl isobutyrate(5919-84-6)

Safety Data

• Hazardous Substances Data: 5919-84-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H18O3/c1-7(2)8(11)12-6-9(3,4)5-10/h7,10H,5-6H2,1-4H3

Upstream product

• 126-30-7 2,2-Dimethyl-1,3-propanediol 
• 79-31-2 isobutyric Acid 
• 406956-07-8 5,5-dimethyl-4-hydroxy-2-isopropyl-1,3-dioxane 
• 79-30-1 isobutyryl chloride 
• 78-84-2 isobutyraldehyde 
• 50-00-0 formaldehyd 

Relevant articles and documents

Retention Indices and Enthalpies of Sorption of Esters of Neopentyl Glycol on DB-1 Stationary Phase

Abstract: The logarithmic retention indices and the enthalpies of sorption at the average temperature of an experiment and 298.2 K are determined via gas–liquid chromatography using DB-1 stationary phase for esters of neopentyl glycol and С2–С

EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE

Masked nitrogen-substituted and oxygen-substituted neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.

Stabilized hydroxypivalaldehyde

In the method of the invention, hydroxypivalaldehyde (3-hydroxy-2,2-dimethylpropanal) and/or its dimer is stored under solid conditions containing an amount of water. By storing such solid conditions, hydroxypivalaldehyde and/or its dimer is stored for a long period of time without reducing its purity.